Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients

Burgess, Carl; Montgomery, Stuart; Wadsworth, J; Turner, Paul

doi:10.1136/pgmj.55.648.704

Cited by 75 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No changes of clinical importance were found in ECG and blood pressure, which is in accordance with the low effect of the two drugs on the cardiovascular system [5].…”

Section: Discussionsupporting

confidence: 80%

“…3]. Nomifensine inhibits the reup take of NA and DA in the synaptic gap, while the effect on 5-HT is weak [4], In clinical studies of both drugs concerned, minor anticholinergic, cardiovascular and sedative effects have been found [5]. Nomifensine shows a central stimulating effect [6], while zimeldine does not differ from placebo in this respect [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Zimeldine versus Nomifensine

Knudsen

Bjørndal²,

Johnsen

et al. 1984

Neuropsychobiology

View full text Add to dashboard Cite

A double-blind comparison of zimeldine, a selective 5-HT reuptake inhibitor, and nomifensme, a noradrenaline and a dopamine reuptake inhibitor, was carried out in 43 inpatients with a scheduled treatment period of 6 weeks. All patients were diagnosed as definite major depressive disorder according to Research Diagnostic Criteria (RDC), and the WHO International Classification of Diseases (ICD-9). The antidepressive efficacy was evaluated by a 10-item subscale of the Comprehensive Psychopathological Rating Scale (CPRS), a clinical global impression (CGI) scale and a self-rating scale (VAMS). Side effects were recorded, and anticholinergic effect was evaluated by parotid saliva volume measurement. No statistically significant differences in efficacy or profile between the two drugs were demonstrable. With the exception of increased sweating in the zimeldine group there were no statistically significant differences in side effects.

show abstract

“…No changes of clinical importance were found in ECG and blood pressure, which is in accordance with the low effect of the two drugs on the cardiovascular system [5].…”

Section: Discussionsupporting

confidence: 80%

Section: Introductionmentioning

confidence: 99%

Zimeldine versus Nomifensine

Knudsen

Bjørndal²,

Johnsen

et al. 1984

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…Similar considerations must apply to the interpretation of our results for PEP/LVET ratio, which showed a tendency to increase during amitriptyline treatment: if pre-ejection period is unaffected by increase in heart rate, but LVET is shortened (Burgess et al, 1979a;Johnson et al, 1981), then the ratio PEP/LVET must inevitably increase as heart rate rises, independently of any drug effects on contractility. Cokkinos and coworkers (1976) showed that PEP/LVET was indeed increased when heart rate rose following atropine administration.…”

Section: Systolic Time Intervals (Sti)mentioning

confidence: 64%

“…Tricyclic antidepressants are widely believed to have depressant rather than stimulant effects on contractility, but there is little evidence that this is so when the drugs are used in therapeutic doses (Glassman & Bigger, 1981) and our results for amitriptyline and QS2 index are concordant with those of Burgess and co-workers (1979a). Most reports on studies with antidepressant drugs on STI have emphasised the effect of the drugs on PEP and PEP/LVET ratio (Burgess et al, 1978(Burgess et al, , 1979aBurckhardt et al, 1978;Taylor & Braithwaite, 1978) and some authors have entirely omitted the results of QS2 measurements (Thayssen et al, 1981).…”

Section: Systolic Time Intervals (Sti)mentioning

confidence: 99%

Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine‐a comparison with amitriptyline and placebo in healthy men.

Warrington¹,

Turner²,

Skrumsager³

1989

Brit J Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Research Division, DK-2860 Soeborg, Copenhagen, Denmark 1 The cardiovascular and anticholinergic effects of femoxetine and amitriptyline were compared with those of placebo in a double-blind cross-over trial in 12 healthy men. The daily doses administered were therapeutic: 600 mg femoxetine and 150 mg amitriptyline. Duration of treatment with each drug was 13 days. 2 The statistically significant effects on systolic time intervals and ECG comprised a larger decrease of QS2 index during femoxetine than during amitriptyline, and an increase of PEP/LVET ratio and QRS duration by amitriptyline. These results suggest that femoxetine and, to a lesser extent, amitriptyline increase contractility compared with placebo, and amitriptyline, but not femoxetine, causes delay in intracardiac conduction. 3 The effects of amitriptyline on the systolic time intervals are difficult to interpret because of the changes in heart rate and intracardiac electrical conduction caused by the drug. These problems of interpretation are discussed. 4 No significant changes in blood pressure were observed. The heart rate during both femoxetine and amitriptyline periods was significantly faster than during the placebo period, amitriptyline causing a significantly greater increase. 5 Salivary secretion was decreased more by amitriptyline (26%) than by femoxetine (8%), the latter being not significantly different from placebo. Femoxetine tended to increase pupil diameter and amitriptyline to increase accommodation near point, but no visual disturbances were reported on any treatment. Symptoms such as dry mouth, constipation and sedation were significantly less frequently reported during femoxetine than during amitriptyline treatment.

show abstract

“…The only consistent effects of decrease in heart rate have been observed also with zimelidine and nomifensine (Burgess et al, 1979). The explanation for this phenomenon remains unknown.…”

Section: Discussionmentioning

confidence: 96%

A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers.

Robinson¹,

Doogan²

1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Fluvoxamine and clovoxamine, two new potential antidepressants were given to 27 healthy male volunteers in a double‐blind, placebo controlled, three‐way crossover study. 2 Neither compound affected the electrical intervals of 24 h ambulant electrocardiographic monitoring with the exception of a small increase in R‐R interval. 3 There were no changes in blood pressure measurements. 4 The only notable unwanted symptom was nausea for both fluvoxamine and clovoxamine.

show abstract

Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients

Cited by 75 publications

References 28 publications

Zimeldine versus Nomifensine

Zimeldine versus Nomifensine

Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine‐a comparison with amitriptyline and placebo in healthy men.

A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers.

Contact Info

Product

Resources

About